Clinical Trials Browser

Phase 2 × Has announcements × Other hematologic neoplasm × Clear all

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04557098 2026-04-13

MajesTEC-1

Phase 2 Active not recruiting

194 enrolled 2 FDA

Other hematologic neoplasm

Hematologic Neoplasms

NCT04634552 2026-04-13

MonumenTAL-1

Phase 2 Recruiting

510 enrolled 2 FDA

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT02981628 2026-02-23

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Phase 2 Recruiting

80 enrolled 1 FDA

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT01784068 2025-09-10

ENESTfreedom

Phase 2 Completed

215 enrolled 7 charts 2 FDA

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01698905 2025-09-02

ENESTop

Phase 2 Completed

163 enrolled 7 charts 2 FDA

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03580655 2025-04-30

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Phase 2 Completed

107 enrolled 2 FDA

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT02000427 2024-05-28

Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia

Phase 2 Completed

45 enrolled 24 charts 2 FDA

LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02435849 2024-02-13

ELIANA

Phase 2 Completed

80 enrolled 39 charts 1 FDA

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Phase 2 Completed

206 enrolled 40 charts 4 FDA

CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

NCT01844765 2021-04-22

DIALOG

Phase 2 Completed

59 enrolled 33 charts 2 FDA

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myeloproliferative Disorders, Neoplastic Processes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01546038 2020-03-03